Better Risk Assessment Tools Needed for Biopharma Stakeholders

The latest report from biopharmaceutical services company Quintiles has looked at the subject of drug development risk.

The healthcare industry needs a clearer, shared understanding of risk to help stakeholders make more informed risk/value decisions, a new report suggests.

Biopharmaceutical services company Quintiles has published its latest annual 'New Health Report', which reveals that healthcare stakeholders have varying perceptions of risk and benefit.

Researchers questioned more than 1,350 biopharmaceutical executives, executives from payer organisations, life science investors and patients with chronic illnesses, both in the US and the UK.

The majority of US payers, NHS executives and investors said biopharmaceutical companies should take on more risk to improve drugs and public health.